LIGACHEM Trademark

Trademark Overview


On Tuesday, August 6, 2024, a trademark application was filed for LIGACHEM with the United States Patent and Trademark Office. The USPTO has given the LIGACHEM trademark a serial number of 79408203. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, October 31, 2024. This trademark is owned by LigaChem Biosciences Inc.. The LIGACHEM trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases,...
ligachem

General Information


Serial Number79408203
Word MarkLIGACHEM
Filing DateTuesday, August 6, 2024
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, October 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesVaccines; food supplements; vitamin preparations; crude medicines for treating cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; nutraceuticals for use as a dietary supplement; biological preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; chemical preparations for medical use for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; syrups for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medicated lozenges for pharmaceutical purposes; capsules sold empty for pharmaceuticals; chemico-pharmaceutical preparations for pharmaceutical or medical purposes, namely, for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibodies for medical purposes; medical antibodies, especially antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; pharmaceutical compositions for use in treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; plant extracts, other than essential oils, for medicinal purposes; pharmaceutical preparations for cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets; pharmaceutical preparations for the treatment and prevention of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; antibiotics; anti-cancer preparations; mixed vitamin preparations; chemotherapeutics; pharmaceutical preparations for the treatment of rare cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, November 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLigaChem Biosciences Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Friday, November 8, 2024LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, October 31, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, November 12, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 12, 2024APPLICATION FILING RECEIPT MAILED